📊 FBRX Key Takeaways
Is FBRX a Good Investment? Thesis Analysis
Forte Biosciences is a pre-commercial stage biopharmaceutical company with minimal revenue ($1.3M) and massive operating losses (-$46.1M), burning substantial cash despite maintaining a strong balance sheet with $93.4M in cash. The company's business model shows no clear path to profitability in the near term, with negative free cash flow of -$34.5M and operating margins of -3507%, indicating fundamental challenges in drug development and commercialization.
Why Buy FBRX? Key Strengths
- Strong liquidity position with $93.4M in cash reserves and 7.34x current ratio providing runway for operations
- Manageable debt load with debt-to-equity ratio of 0.26x and no immediate solvency concerns
- Revenue growth of 16.9% year-over-year demonstrates some commercial progress, albeit from an extremely small base
FBRX Investment Risks to Consider
- Unsustainable cash burn rate of $34.4M in operating cash flow will deplete capital reserves within 2-3 years without achieving profitability or securing additional financing
- Operating losses of $46.1M against $1.3M in revenue indicate severe clinical-stage company economics with no clear evidence of successful product commercialization
- Negative interest coverage ratio of -61.0x and negative returns on equity (-53.0%) and assets (-45.9%) demonstrate the company cannot service debt or generate returns from its asset base
Key Metrics to Watch
- Cash burn rate and remaining runway - monitor quarterly operating cash flow to assess sustainability
- Revenue growth trajectory and product commercialization progress - critical to determine if revenue can scale meaningfully
- Clinical trial results and regulatory progress - essential for validating pipeline and potential future revenue opportunities
- Operating expense management - evaluate ability to achieve profitability or reduce burn rate
FBRX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.34x current ratio provides a solid financial cushion.
FBRX Profitability Ratios
FBRX vs Healthcare Sector
How Forte Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FBRX Overvalued or Undervalued?
Based on fundamental analysis, Forte Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FBRX Balance Sheet & Liquidity
FBRX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Forte Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-24.92 indicates the company is currently unprofitable.
FBRX Growth Metrics (YoY)
FBRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2020 | $9.0K | -$10.3M | N/A |
| Q3 2019 | $9.0K | -$352.0K | N/A |
| Q2 2019 | $9.0K | -$16.0M | N/A |
| Q1 2019 | $9.0K | -$12.9M | N/A |
| Q3 2018 | $10.0K | -$352.0K | N/A |
| Q2 2018 | $9.0K | -$9.1M | N/A |
| Q1 2018 | N/A | -$9.1M | N/A |
| Q3 2017 | N/A | -$9.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FBRX Capital Allocation
FBRX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Forte Biosciences, Inc. (CIK: 0001419041)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jan 13, 2026 | 4 | xslF345X05/form4-01132026_090120.xml | View → |
| Jan 13, 2026 | 4 | xslF345X05/form4-01132026_090104.xml | View → |
| Jan 2, 2026 | 4 | xslF345X05/form4-01022026_090147.xml | View → |
| Jan 2, 2026 | 4 | xslF345X05/form4-01022026_090140.xml | View → |
| Nov 14, 2025 | 10-Q | fbrx-20250930.htm | View → |
❓ Frequently Asked Questions about FBRX
What is the AI rating for FBRX?
Forte Biosciences, Inc. (FBRX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBRX's key strengths?
Claude: Strong liquidity position with $93.4M in cash reserves and 7.34x current ratio providing runway for operations. Manageable debt load with debt-to-equity ratio of 0.26x and no immediate solvency concerns.
What are the risks of investing in FBRX?
Claude: Unsustainable cash burn rate of $34.4M in operating cash flow will deplete capital reserves within 2-3 years without achieving profitability or securing additional financing. Operating losses of $46.1M against $1.3M in revenue indicate severe clinical-stage company economics with no clear evidence of successful product commercialization.
What is FBRX's revenue and growth?
Forte Biosciences, Inc. reported revenue of $1.3M.
Does FBRX pay dividends?
Forte Biosciences, Inc. does not currently pay dividends.
Where can I find FBRX SEC filings?
Official SEC filings for Forte Biosciences, Inc. (CIK: 0001419041) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBRX's EPS?
Forte Biosciences, Inc. has a diluted EPS of $-3.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FBRX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Forte Biosciences, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FBRX stock overvalued or undervalued?
Valuation metrics for FBRX: ROE of -53.0% (sector avg: 15%), net margin of -3,393.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FBRX stock in 2026?
Our dual AI analysis gives Forte Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FBRX's free cash flow?
Forte Biosciences, Inc.'s operating cash flow is $-34.4M, with capital expenditures of $116.0K. FCF margin is -2,628.0%.
How does FBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,393.2% (avg: 12%), ROE -53.0% (avg: 15%), current ratio 7.34 (avg: 2).